Organogenesis Reports Prelim Q4, 2020 Financial Results

 Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported preliminary financial results for the three months and twelve months ended December 31, 2020.

Fourth Quarter 2020 Preliminary Financial Results Summary:

• Net revenue of between $104.6 million and $106.0 million for the three months ended December 31, 2020, up 40% to 42% compared to net revenue of $74.6 million for the three months ended December 31, 2019.
  Net revenue is based upon:
  ○  Net revenue from Advanced Wound Care products of between $92.0 million and $93.2 million, up 45% to 47% year-over-year.
  ○  Net revenue from Surgical & Sports Medicine products of between $12.6 million and $12.8 million, up 12% to 14% year-over-year.
• Net revenue from the sale of PuraPly products of between $43.8 million and $44.6 million for the three months ended December 31, 2020, up 10% to 12% year-over-year.
• The Company expects to report positive GAAP net income and positive Adjusted EBITDA for the three months ended December 31, 2020.
  

Fiscal Year 2020 Preliminary Financial Results Summary:

• Net revenue of between $336.1 million and $337.5 million for the twelve months ended December 31, 2020, up approximately 29% compared to net revenue of $261 million for the twelve months ended December 31, 2019.
  Net revenue is based upon:
  ○  Net revenue from Advanced Wound Care products of between $293.0 million and $294.2 million, up approximately 33% year-over-year.
  ○  Net revenue from Surgical & Sports Medicine products of between $43.1 million and $43.3 million, up 7% to 8% year-over-year.
• Net revenue from the sale of PuraPly products of between $145.8 million and $146.6 million for the twelve months ended December 31, 2020, up 15% to 16% year-over-year.
• The Company expects to report positive GAAP net income and positive Adjusted EBITDA for the full fiscal year 2020 period.

https://www.globenewswire.com/news-release/2021/01/13/2158251/0/en/Organogenesis-Holdings-Inc-Reports-Preliminary-Financial-Results-for-Fourth-Quarter-and-Fiscal-Year-2020.html